You are here

Bristol Myers posts quarterly loss, revenue increases by 5%

The organization anticipates that its malignant growth immunotherapy should lose patent insurance not long from now and has gone to outside assets to recharge its medication advancement pipeline. Bristol Myers Squibb revealed a first-quarter misfortune on Thursday as costs connected with its new acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% ascent in deals. Bristol Myers